<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>60</patient-age><report-id>FR-SANOFI-AVENTIS-2013SA004419</report-id><gender>female</gender><reactions><reaction>pulmonary embolism</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>LOVENOX</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10043634</indication></indications><patient-age>60</patient-age><outcomes><outcome>Death</outcome></outcomes><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>78952</messagenumb>
<messagesenderidentifier>SAAVPROD</messagesenderidentifier>
<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20130125152600</messagedate>
</ichicsrmessageheader>
<safetyreport>
<safetyreportversion>1</safetyreportversion>
<safetyreportid>FR-SANOFI-AVENTIS-2013SA004419</safetyreportid>
<primarysourcecountry>FR</primarysourcecountry>
<occurcountry>FR</occurcountry>
<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>2013-01-25</transmissiondate>
<reporttype>1</reporttype>
<serious code="1">Yes</serious>
<seriousnessdeath>1</seriousnessdeath>
<seriousnesslifethreatening>2</seriousnesslifethreatening>
<seriousnesshospitalization>2</seriousnesshospitalization>
<seriousnessdisabling>2</seriousnessdisabling>
<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
<receivedateformat>102</receivedateformat>
<receivedate>2013-01-18</receivedate>
<receiptdateformat>102</receiptdateformat>
<receiptdate>2013-01-18</receiptdate>
<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
<companynumb>FR-SANOFI-AVENTIS-2013SA004419</companynumb>
<primarysource>
<reportergivename>PRIVACY</reportergivename>
<reportermiddlename>PRIVACY</reportermiddlename>
<reporterfamilyname>PRIVACY</reporterfamilyname>
<reporterstreet>PRIVACY</reporterstreet>
<reportercity>PRIVACY</reportercity>
<reportercountry>FR</reportercountry>
<qualification code="5">Consumer or non-health professional</qualification>
</primarysource>
<sender>
<sendertype>1</sendertype>
<senderorganization>sanofi-aventis</senderorganization>
<senderdepartment>US Affiliate Pharmacovigilance</senderdepartment>
<sendergivename>Barbara</sendergivename>
<senderfamilyname>Rullo</senderfamilyname>
<senderstreetaddress>55A-435 55 Corporate Drive</senderstreetaddress>
<sendercity>Bridgewater</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>08807</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>9089816698</sendertel>
<sendertelcountrycode>1</sendertelcountrycode>
<senderfax>9089877894</senderfax>
<senderfaxcountrycode>1</senderfaxcountrycode>
<senderemailaddress>Barbara.Rullo@sanofi-aventis.com</senderemailaddress>
</sender>
<receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Center for Drug Evaluation and Research</receiverdepartment>
<receiverstreetaddress>5600 Fishers lane</receiverstreetaddress>
<receivercity>Rockville</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20857</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>3018273237</receivertel>
<receivertelcountrycode>1</receivertelcountrycode>
<receiveremailaddress>aersesub@cder.fda.gov</receiveremailaddress>
</receiver>
<patient>
<patientinitial>PRIVACY</patientinitial>
<patientonsetage>60</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientagegroup>5</patientagegroup>
<patientsex code="2">Female</patientsex>
<patientdeath>
<patientdeathdateformat>102</patientdeathdateformat>
<patientdeathdate>20130105</patientdeathdate>
<patientautopsyyesno>3</patientautopsyyesno>
<patientdeathcause>
<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
<patientdeathreport>10037377</patientdeathreport>
</patientdeathcause>
</patientdeath>
<reaction>
<primarysourcereaction>pulmonary embolism</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10037377</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionfirsttime>1</reactionfirsttime>
<reactionfirsttimeunit>802</reactionfirsttimeunit>
<reactionoutcome code="5">fatal</reactionoutcome>
</reaction>
<drug>
<drugcharacterization code="1">suspsect</drugcharacterization>
<medicinalproduct>LOVENOX</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugauthorizationnumb>NDA 20-164</drugauthorizationnumb>
<drugstructuredosagenumb>6000</drugstructuredosagenumb>
<drugstructuredosageunit code="025"/>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
<drugdosageform normalized="injection">INJECTION</drugdosageform>
<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10043634</drugindication>
<drugstartperiod>1</drugstartperiod>
<drugstartperiodunit>802</drugstartperiodunit>
<actiondrug code="6">Not Applicable</actiondrug>
<activesubstance>
<activesubstancename>ENOXAPARIN SODIUM</activesubstancename>
</activesubstance>
</drug>
<summary>
<narrativeincludeclinical>This serious unsolicited report from France (Local reference number: 2013-FRA 000405) was received on 18-Jan 2013 from a consumer for his mother and <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a <Semaphore x="1387834" class="Patient Age" value="60" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="60" score="1.00" ID="">60 </Semaphore>year old </Semaphore>female patient who died due to <Semaphore x="2438586" class="Disease or Finding" value="Pulmonary Embolism" score="1.00" ID="C50713">pulmonary embolism </Semaphore>whilst receiving <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="530331" class="Medicine" value="Enoxaparin sodium" score="0.74" ID="249134">enoxaparin <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium </Semaphore></Semaphore>(<Semaphore x="799774" class="Medicine" value="Lovenox" score="0.49" ID="249254">Lovenox</Semaphore>) for <Semaphore x="2614723" class="Disease or Finding" value="Thrombosis" score="1.00" ID="C26891">thrombosis </Semaphore><Semaphore x="2420563" class="Procedure" value="Preventive Intervention" score="1.00" ID="C15843">prophylaxis</Semaphore>.On an unknown date, the patient had experienced <Semaphore x="1528253" class="Disease or Finding" value="Ankle Fracture" score="1.00" ID="C26989">ankle fracture</Semaphore>. She was immobilized and was using a wheelchair. On an unknown date, she started receiving subcutaneous <Semaphore x="530331" class="Medicine" value="Enoxaparin sodium" score="0.74" ID="249134">enoxaparin <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium </Semaphore></Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore>6000 IU daily (batch/ lot number and expiry date <Semaphore x="2665498" class="AnatomicStructure" value="Unspecified Anatomic Sites" score="1.00" ID="C13411">not specified</Semaphore>). The patient had injected the <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injections </Semaphore>of <Semaphore x="530375" class="Medicine" value="Enoxaparin" score="0.74" ID="279302">enoxaparin </Semaphore>herself. One month after <Semaphore x="530375" class="Medicine" value="Enoxaparin" score="0.74" ID="279302">enoxaparin </Semaphore>initiation<Semaphore x="2438586" class="Disease or Finding" value="Pulmonary Embolism" score="1.00" ID="C50713">, she experienced <Semaphore x="2438586" class="Disease or Finding" value="Pulmonary Embolism" score="1.00" ID="C50713">pulmonary embolism </Semaphore></Semaphore>leading to <Semaphore x="1837270" class="Disease or Finding" value="Death" score="1.00" ID="C28554">death </Semaphore>on 05-Jan 2013. It was unknown if <Semaphore x="1558453" class="Disease or Finding" value="Autopsy TNM Finding" score="1.00" ID="C48882">Autopsy </Semaphore>was done.Patient슿s medical history and concomitant medication, if any, were not provided.<Semaphore x="1947545" class="Race" value="French" score="1.00" ID="C43854">French </Semaphore>imputability: C1S1B2No further information was provided.</narrativeincludeclinical>
<sendercomment>Sanofi-Aventis company comment dated 21-Jan-2013: Based on the available information causal role of enoxaparin sodium cannot be denied for the event of pulmonary embolism leading to fatal outcome, however alternative explanation for the same is patient슿s underlying condition.</sendercomment>
</summary>
</patient>
</safetyreport>
</ichicsr></original></faers>